[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fXI_8-HYDJBHWzxo5dtR4LvGM50EJbnH_5VNC-qG15ms":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":31,"phaseBuckets":47,"rows":54},"University Hospital Bispebjerg and Frederiksberg",[4],66,false,21,2,267120,4,55,[14,16,19,21,23,25,27,29],{"name":15,"count":11},"Depression",{"name":17,"count":18},"Stroke",3,{"name":20,"count":18},"Sphenopalatine Ganglion Block",{"name":22,"count":18},"Atrial Fibrillation",{"name":24,"count":9},"Malignant Melanoma",{"name":26,"count":9},"Diabetes Mellitus",{"name":28,"count":9},"Perioperative Complication",{"name":30,"count":9},"Microvascular Disease",[32,37,42],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT06402396","Assessing Pain by the painDETECT Questionnaire (PDQ)","2019-12-01","bDMARDS",{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06184581","Lithium Versus Lamotrigine in Bipolar Disorder, Type II","2027-12-01","Lithium Carbonate",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07346716","Medicines in Breast Milk and Estimated Infant Exposure","2028-01","Prescription Drugs",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,80,98,124,150,180,198,216,234,261,279,306,332,350,379,406,437,464],{"intervention":41,"totalTrials":56,"cells":57},1,{"EARLY_PHASE1":58,"PHASE1":61,"PHASE2":63,"PHASE3":65,"PHASE4":67,"NA":78},{"trials":59,"activeCount":60},[],0,{"trials":62,"activeCount":60},[],{"trials":64,"activeCount":60},[],{"trials":66,"activeCount":60},[],{"trials":68,"activeCount":56,"soonestReadout":40},[69],{"nctId":38,"briefTitle":39,"status":70,"phases":71,"primaryCompletion":40,"completion":40,"start":72,"enrollment":73,"conditions":74,"interventions":76},"RECRUITING",[52],"2024-05-08",200,[75],"Bipolar II Disorder",[41,77],"Lamotrigine",{"trials":79,"activeCount":60},[],{"intervention":77,"totalTrials":56,"cells":81},{"EARLY_PHASE1":82,"PHASE1":84,"PHASE2":86,"PHASE3":88,"PHASE4":90,"NA":96},{"trials":83,"activeCount":60},[],{"trials":85,"activeCount":60},[],{"trials":87,"activeCount":60},[],{"trials":89,"activeCount":60},[],{"trials":91,"activeCount":56,"soonestReadout":40},[92],{"nctId":38,"briefTitle":39,"status":70,"phases":93,"primaryCompletion":40,"completion":40,"start":72,"enrollment":73,"conditions":94,"interventions":95},[52],[75],[41,77],{"trials":97,"activeCount":60},[],{"intervention":36,"totalTrials":56,"cells":99},{"EARLY_PHASE1":100,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":108,"NA":110},{"trials":101,"activeCount":60},[],{"trials":103,"activeCount":60},[],{"trials":105,"activeCount":60},[],{"trials":107,"activeCount":60},[],{"trials":109,"activeCount":60},[],{"trials":111,"activeCount":56,"soonestReadout":35},[112],{"nctId":33,"briefTitle":34,"status":113,"phases":114,"primaryCompletion":35,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":123},"ACTIVE_NOT_RECRUITING",[],"2027-01-01","2013-01",7056,[119,120,121,122],"Inflammatory Arthritis","Spondylarthropathies","Rheumatoid Arthritis","Psoriatic Arthritis",[36],{"intervention":46,"totalTrials":56,"cells":125},{"EARLY_PHASE1":126,"PHASE1":128,"PHASE2":130,"PHASE3":132,"PHASE4":134,"NA":136},{"trials":127,"activeCount":60},[],{"trials":129,"activeCount":60},[],{"trials":131,"activeCount":60},[],{"trials":133,"activeCount":60},[],{"trials":135,"activeCount":60},[],{"trials":137,"activeCount":56,"soonestReadout":45},[138],{"nctId":43,"briefTitle":44,"status":70,"phases":139,"primaryCompletion":45,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":149},[],"2030-01","2024-12-20",250,[144,145,146,147,148],"Breastfeeding","Medication Safety","Lactation","Drug Exposure Via Breast Milk","Pharmacokinetic Parameters",[46],{"intervention":151,"totalTrials":56,"cells":152},"Glucagon",{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":178},{"trials":154,"activeCount":60},[],{"trials":156,"activeCount":60},[],{"trials":158,"activeCount":60},[],{"trials":160,"activeCount":60},[],{"trials":162,"activeCount":60},[163],{"nctId":164,"briefTitle":165,"status":166,"phases":167,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":171,"interventions":174},"NCT03533179","Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition","COMPLETED",[52],"2019-10-01","2018-06-01",10,[172,173],"Drug Overdose","Overdose of Beta-adrenergic Blocking Drug",[151,175,176,177],"Esmolol","Physiologic saline - glucagon dummy","Physiologic saline - esmolol dummy",{"trials":179,"activeCount":60},[],{"intervention":175,"totalTrials":56,"cells":181},{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":186,"PHASE3":188,"PHASE4":190,"NA":196},{"trials":183,"activeCount":60},[],{"trials":185,"activeCount":60},[],{"trials":187,"activeCount":60},[],{"trials":189,"activeCount":60},[],{"trials":191,"activeCount":60},[192],{"nctId":164,"briefTitle":165,"status":166,"phases":193,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":194,"interventions":195},[52],[172,173],[151,175,176,177],{"trials":197,"activeCount":60},[],{"intervention":176,"totalTrials":56,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":214},{"trials":201,"activeCount":60},[],{"trials":203,"activeCount":60},[],{"trials":205,"activeCount":60},[],{"trials":207,"activeCount":60},[],{"trials":209,"activeCount":60},[210],{"nctId":164,"briefTitle":165,"status":166,"phases":211,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":212,"interventions":213},[52],[172,173],[151,175,176,177],{"trials":215,"activeCount":60},[],{"intervention":177,"totalTrials":56,"cells":217},{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":226,"NA":232},{"trials":219,"activeCount":60},[],{"trials":221,"activeCount":60},[],{"trials":223,"activeCount":60},[],{"trials":225,"activeCount":60},[],{"trials":227,"activeCount":60},[228],{"nctId":164,"briefTitle":165,"status":166,"phases":229,"primaryCompletion":168,"completion":168,"start":169,"enrollment":170,"conditions":230,"interventions":231},[52],[172,173],[151,175,176,177],{"trials":233,"activeCount":60},[],{"intervention":235,"totalTrials":56,"cells":236},"Oxygen",{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":245,"NA":259},{"trials":238,"activeCount":60},[],{"trials":240,"activeCount":60},[],{"trials":242,"activeCount":60},[],{"trials":244,"activeCount":60},[],{"trials":246,"activeCount":60},[247],{"nctId":248,"briefTitle":249,"status":166,"phases":250,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":257},"NCT03494387","VitamIn and oXygen Interventions and Cardiovascular Events",[52],"2020-03-01","2020-03-24","2018-04-06",600,[256],"Postoperative Cardiac Complication",[235,258],"Antioxidants",{"trials":260,"activeCount":60},[],{"intervention":258,"totalTrials":56,"cells":262},{"EARLY_PHASE1":263,"PHASE1":265,"PHASE2":267,"PHASE3":269,"PHASE4":271,"NA":277},{"trials":264,"activeCount":60},[],{"trials":266,"activeCount":60},[],{"trials":268,"activeCount":60},[],{"trials":270,"activeCount":60},[],{"trials":272,"activeCount":60},[273],{"nctId":248,"briefTitle":249,"status":166,"phases":274,"primaryCompletion":251,"completion":252,"start":253,"enrollment":254,"conditions":275,"interventions":276},[52],[256],[235,258],{"trials":278,"activeCount":60},[],{"intervention":280,"totalTrials":56,"cells":281},"Tadalafil 40 MG",{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":298,"PHASE3":300,"PHASE4":302,"NA":304},{"trials":283,"activeCount":60},[],{"trials":285,"activeCount":60},[286],{"nctId":287,"briefTitle":288,"status":166,"phases":289,"primaryCompletion":290,"completion":291,"start":292,"enrollment":293,"conditions":294,"interventions":297},"NCT05095077","Effects of Single Dose Tadalafil on Urethral and Anal Closure Function",[49],"2021-12-30","2022-01-01","2021-08-01",24,[295,296],"Urinary Incontinence,Stress","Fecal Incontinence",[280],{"trials":299,"activeCount":60},[],{"trials":301,"activeCount":60},[],{"trials":303,"activeCount":60},[],{"trials":305,"activeCount":60},[],{"intervention":307,"totalTrials":56,"cells":308},"Citalopram 40mg",{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":324,"PHASE3":326,"PHASE4":328,"NA":330},{"trials":310,"activeCount":60},[],{"trials":312,"activeCount":60},[313],{"nctId":314,"briefTitle":315,"status":166,"phases":316,"primaryCompletion":317,"completion":318,"start":319,"enrollment":293,"conditions":320,"interventions":322},"NCT04097288","Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects",[49],"2020-02-01","2020-05-01","2019-09-17",[321,296],"Stress Urinary Incontinence",[307,323],"Reboxetine 8 mg",{"trials":325,"activeCount":60},[],{"trials":327,"activeCount":60},[],{"trials":329,"activeCount":60},[],{"trials":331,"activeCount":60},[],{"intervention":323,"totalTrials":56,"cells":333},{"EARLY_PHASE1":334,"PHASE1":336,"PHASE2":342,"PHASE3":344,"PHASE4":346,"NA":348},{"trials":335,"activeCount":60},[],{"trials":337,"activeCount":60},[338],{"nctId":314,"briefTitle":315,"status":166,"phases":339,"primaryCompletion":317,"completion":318,"start":319,"enrollment":293,"conditions":340,"interventions":341},[49],[321,296],[307,323],{"trials":343,"activeCount":60},[],{"trials":345,"activeCount":60},[],{"trials":347,"activeCount":60},[],{"trials":349,"activeCount":60},[],{"intervention":351,"totalTrials":56,"cells":352},"Inspiratory oxygen fraction",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":357,"PHASE3":359,"PHASE4":361,"NA":363},{"trials":354,"activeCount":60},[],{"trials":356,"activeCount":60},[],{"trials":358,"activeCount":60},[],{"trials":360,"activeCount":60},[],{"trials":362,"activeCount":60},[],{"trials":364,"activeCount":60},[365],{"nctId":366,"briefTitle":367,"status":368,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":378},"NCT04540276","Intraoperative Hyperoxia and MINS","UNKNOWN",[],"2020-10-01","2021-03-01","2018-02-04",7700,[375,376,377],"Hyperoxia","Myocardial Infarction","Myocardial Injury",[351],{"intervention":380,"totalTrials":56,"cells":381},"Paracetamol",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":392},{"trials":383,"activeCount":60},[],{"trials":385,"activeCount":60},[],{"trials":387,"activeCount":60},[],{"trials":389,"activeCount":60},[],{"trials":391,"activeCount":60},[],{"trials":393,"activeCount":60},[394],{"nctId":395,"briefTitle":396,"status":368,"phases":397,"primaryCompletion":398,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":405},"NCT04523740","Paracetamol Discontinuation in the Elderly After Long-term Consumption",[53],"2021-12","2020-08",98,[402,403,404],"Pain, Chronic","Pain, Medication","Pain, Discontinuation",[380],{"intervention":407,"totalTrials":56,"cells":408},"Levodopa",{"EARLY_PHASE1":409,"PHASE1":411,"PHASE2":413,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":410,"activeCount":60},[],{"trials":412,"activeCount":60},[],{"trials":414,"activeCount":60},[],{"trials":416,"activeCount":60},[],{"trials":418,"activeCount":60},[],{"trials":420,"activeCount":60},[421],{"nctId":422,"briefTitle":423,"status":166,"phases":424,"primaryCompletion":425,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":436},"NCT06275633","Behavioural Profiling of Disease-related Cognitive and Motor Impairment in PD",[53],"2021-12-03","2023-07-30","2019-03-19",68,[430,431,432,433,434,15,435,407],"Parkinson Disease","Medication","UPDRS","Motor Function","Cognitive Impairment","Impulsive",[407],{"intervention":438,"totalTrials":56,"cells":439},"Phenylephrine's effect on brain oxygenation",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":450},{"trials":441,"activeCount":60},[],{"trials":443,"activeCount":60},[],{"trials":445,"activeCount":60},[],{"trials":447,"activeCount":60},[],{"trials":449,"activeCount":60},[],{"trials":451,"activeCount":60},[452],{"nctId":453,"briefTitle":454,"status":166,"phases":455,"primaryCompletion":370,"completion":370,"start":456,"enrollment":457,"conditions":458,"interventions":462},"NCT03682198","Neuro-Ox 2018: Assessment of Cerebral Oxygenation Under Three Clinically Relevant Conditions",[53],"2018-09-24",18,[459,460,461],"Neurosurgery","Elective Craniotomy","General Anaesthesia",[438,463],"Normal vs. high inspired oxygen",{"intervention":463,"totalTrials":56,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":467,"activeCount":60},[],{"trials":469,"activeCount":60},[],{"trials":471,"activeCount":60},[],{"trials":473,"activeCount":60},[],{"trials":475,"activeCount":60},[],{"trials":477,"activeCount":60},[478],{"nctId":453,"briefTitle":454,"status":166,"phases":479,"primaryCompletion":370,"completion":370,"start":456,"enrollment":457,"conditions":480,"interventions":481},[53],[459,460,461],[438,463]]